Published in Curr Neuropharmacol on January 01, 2017
FMRP regulates an ethanol-dependent shift in GABABR function and expression with rapid antidepressant properties. Nat Commun (2016) 0.76
New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity. Neural Plast (2017) 0.75
Expanding frontiers in weight-control research explored by young investigators. J Physiol Sci (2016) 0.75
Investigational drugs in recent clinical trials for treatment-resistant depression. Expert Rev Neurother (2017) 0.75
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology (2017) 0.75
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 34.83
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 10.91
Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol (1997) 10.26
The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol (2011) 9.40
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry (2013) 4.84
Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc Natl Acad Sci U S A (1997) 4.03
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry (2010) 4.00
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol (2008) 3.90
Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry (2011) 3.62
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry (2009) 3.04
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry (2012) 2.74
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc Natl Acad Sci U S A (1993) 2.37
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction (2009) 2.14
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol (1990) 1.82
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res (2011) 1.80
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol (2011) 1.79
Taming the ketamine tiger. 1965. Anesthesiology (2010) 1.77
A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76
A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry (2014) 1.69
N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia. Biol Psychiatry (2014) 1.60
Dextromethorphan as a potential rapid-acting antidepressant. Med Hypotheses (2011) 1.52
Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med (2014) 1.52
Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol (2001) 1.45
Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs (2012) 1.38
Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7. Eur J Neurosci (2003) 1.36
Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology (2014) 1.33
Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction (2009) 1.30
mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade. Int J Neuropsychopharmacol (2011) 1.28
Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A (2014) 1.26
Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety (2014) 1.26
Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl) (2007) 1.22
MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology (2004) 1.20
A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol (2012) 1.20
Metabotropic glutamate receptors: phosphorylation and receptor signaling. J Neurosci Res (2008) 1.19
Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry (2013) 1.19
Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav (2011) 1.18
Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord (2014) 1.18
Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol (2014) 1.17
A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology (2008) 1.12
Serial infusions of low-dose ketamine for major depression. J Psychopharmacol (2013) 1.12
Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res (2014) 1.09
AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets (2007) 1.08
AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets (2007) 1.08
GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs (2013) 1.07
The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging (2009) 1.05
Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med (2010) 1.04
Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat (2013) 1.02
The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol (2015) 1.00
Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract (2015) 1.00
Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00
A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol (2012) 1.00
Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav (2005) 0.99
Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther (1999) 0.99
Activation of the mGlu7 receptor elicits antidepressant-like effects in mice. Psychopharmacology (Berl) (2007) 0.97
Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet (2011) 0.97
Ketamine and other potential glutamate antidepressants. Psychiatry Res (2014) 0.96
Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry (2015) 0.96
Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology (2012) 0.96
Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res (2014) 0.95
Glycine-like modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation. J Neurochem (1991) 0.92
Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord (2006) 0.92
Possible antidepressant effects and mechanisms of memantine in behaviors and synaptic plasticity of a depression rat model. Neuroscience (2011) 0.92
Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Aust N Z J Psychiatry (2014) 0.91
Examination of Org 26576, an AMPA receptor positive allosteric modulator, in patients diagnosed with major depressive disorder: an exploratory, randomized, double-blind, placebo-controlled trial. J Psychopharmacol (2012) 0.90
N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord (2002) 0.90
Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med (2013) 0.89
Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol (2013) 0.89
The mGluR7 allosteric agonist AMN082 produces antidepressant-like effects by modulating glutamatergic signaling. Pharmacol Biochem Behav (2011) 0.89
Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull (2009) 0.89
An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Med Hypotheses (2012) 0.88
Prefrontal changes and treatment response prediction in depression. Semin Clin Neuropsychiatry (2001) 0.87
Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. J Psychopharmacol (2013) 0.87
Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology (2014) 0.87
Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry (2015) 0.86
A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 - estimating occupancy in the absence of a reference region. Neuroimage (2013) 0.85
Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry (2009) 0.85
Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry (2008) 0.85
Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry (2012) 0.85
The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Affect Disord (2012) 0.85
Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: role of brain-derived neurotrophic factor. Neuroscience (2012) 0.83
Does increasing the ratio of AMPA-to-NMDA receptor mediated neurotransmission engender antidepressant action? Studies in the mouse forced swim and tail suspension tests. Neurosci Lett (2013) 0.82
NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacol Rep (2011) 0.82
Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med (2008) 0.81
Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression. Behav Brain Res (2014) 0.80
Neurocognitive function and schizophrenia-proneness in individuals dependent on ketamine, on high potency cannabis ('skunk') or on cocaine. Pharmacopsychiatry (2012) 0.79
Comparison of hippocampal metabotropic glutamate receptor 7 (mGlu7) mRNA levels in two animal models of depression. Neurosci Lett (2010) 0.79
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression. Aust N Z J Psychiatry (2015) 0.78
Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol (2015) 0.77
Dextromethorphan and quinidine combination in emotional lability associated with depression: a case report. Prim Care Companion CNS Disord (2012) 0.77
Concerns about dextromethorphan as a potential rapid-acting antidepressant. Med Hypotheses (2011) 0.76
Sequence-specific chemical modification of chromatin DNA with reactive derivatives of oligonucleotides. Mol Biol Rep (1990) 0.75
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry (2005) 1.51
The effects of tryptophan depletion on neural responses to emotional words in remitted depression. Biol Psychiatry (2009) 1.50
Suicide risk in youth with intellectual disabilities: the challenges of screening. J Dev Behav Pediatr (2012) 1.43
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
Selective reduction in amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation. Biol Psychiatry (2005) 1.37
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biol Psychiatry (2010) 1.32
NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A (2012) 1.32
Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant major depression. Biol Psychiatry (2013) 1.31
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry (2006) 1.23
Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry (2013) 1.21
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. Neuroimage (2010) 1.16
Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage (2009) 1.16
Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. Biol Psychiatry (2012) 1.12
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Grey matter differences in bipolar disorder: a meta-analysis of voxel-based morphometry studies. Bipolar Disord (2012) 1.11
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09
Suicide screening in schools, primary care and emergency departments. Curr Opin Pediatr (2009) 1.08
Reduced posterior hippocampal volume in posttraumatic stress disorder. J Clin Psychiatry (2008) 1.08
Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology (2008) 1.07
Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep (2011) 1.05
Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.03
Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography. Arch Gen Psychiatry (2008) 1.02
Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry (2014) 1.00
Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00
Defining anxious depression: a review of the literature. CNS Spectr (2013) 0.99
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) (2013) 0.98
No change in serotonin type 1A receptor binding in patients with posttraumatic stress disorder. Am J Psychiatry (2005) 0.98
Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry (2013) 0.98
Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry (2006) 0.97
An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol (2011) 0.97
Bcl-2 polymorphism influences gray matter volume in the ventral striatum in healthy humans. Biol Psychiatry (2009) 0.95
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety (2013) 0.95
Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder? Neurobiol Dis (2010) 0.94
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) (2014) 0.93
Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett (2011) 0.93
Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach. World J Biol Psychiatry (2013) 0.93
Neurobiology of anxious depression: a review. Depress Anxiety (2013) 0.93
Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int J Neuropsychopharmacol (2010) 0.92
Baseline mood-state measures as predictors of antidepressant response to scopolamine. Psychiatry Res (2012) 0.89
Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. Brain Res Bull (2011) 0.89
Growing up in the hospital. JAMA (2007) 0.89
A functionally atypical amidating enzyme from the human parasite Schistosoma mansoni. FASEB J (2004) 0.89
Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin Ther Targets (2014) 0.89
Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder. CNS Spectr (2013) 0.88
Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res (2011) 0.88
The immunology of bipolar disorder. Neuroimmunomodulation (2014) 0.87
Habenula volume in post-traumatic stress disorder measured with high-resolution MRI. Biol Mood Anxiety Disord (2011) 0.85
Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology (2012) 0.84
DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. Int J Neuropsychopharmacol (2013) 0.83
The impact of the CACNA1C risk allele on limbic structures and facial emotions recognition in bipolar disorder subjects and healthy controls. J Affect Disord (2012) 0.83
Association of the COMT Met¹⁵⁸ allele with trait impulsivity in healthy young adults. Mol Med Rep (2013) 0.83
Cognitive dysfunction in depression - pathophysiology and novel targets. CNS Neurol Disord Drug Targets (2014) 0.83
Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol (2013) 0.83
Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment. Eur Arch Psychiatry Clin Neurosci (2014) 0.82
Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders. CNS Drugs (2015) 0.82
Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychother Psychosom (2014) 0.81
BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry (2014) 0.81
A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania. Hum Psychopharmacol (2005) 0.81
Novel biomarkers for bipolar disorder. Expert Opin Med Diagn (2012) 0.81
Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology (Berl) (2014) 0.81
Leukocyte mitochondrial DNA copy number in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.81
Association between subcortical volumes and verbal memory in unmedicated depressed patients and healthy controls. Neuropsychologia (2012) 0.80
Demographic and clinical characteristics of consistent and inconsistent longitudinal reporters of lifetime suicide attempts in adolescence through young adulthood. Depress Anxiety (2013) 0.80
Catecholamine depletion in first-degree relatives of individuals with mood disorders: An [(18)F]fluorodeoxyglucose positron emission tomography study. Neuroimage Clin (2013) 0.79
Psychotropic medication use in pediatric patients with cancer. Arch Pediatr Adolesc Med (2006) 0.79
COMT Met (158) modulates facial emotion recognition in bipolar I disorder mood episodes. J Affect Disord (2012) 0.79
Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder. CNS Spectr (2013) 0.79
Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology (Berl) (2013) 0.79
Self-Reported Recent Life Stressors and Risk of Suicide in Pediatric Emergency Department Patients. Clin Pediatr Emerg Med (2013) 0.79
COMT polymorphisms as predictors of cognitive dysfunction during manic and mixed episodes in bipolar I disorder. Bipolar Disord (2012) 0.78
Effects of arterial cannulation stress on regional cerebral blood flow in major depressive disorder. Sci Rep (2012) 0.78
NEUROBIOLOGICAL ASPECTS OF SUICIDE AND SUICIDE ATTEMPTS IN BIPOLAR DISORDER. Transl Neurosci (2013) 0.78
Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Hum Psychopharmacol (2015) 0.78
Gender effects of the COMT Val 158 Met genotype on verbal fluency in healthy adults. Mol Med Rep (2013) 0.78
[Neuropatological and neurochemical abnormalities in bipolar disorder]. Rev Bras Psiquiatr (2004) 0.77
Latent class analysis of substance use and aggressive behavior in reservation-based American Indian youth who attempted suicide. Am Indian Alsk Native Ment Health Res (2015) 0.77
Reduced activities of phospholipases A2 in platelets of drug-naïve bipolar disorder patients. Bipolar Disord (2014) 0.77